Working to transform lives through the development of innovative IL-1β therapies

At Avalo, we’re 100% focused on developing treatments for immune-mediated inflammatory diseases with large unmet needs that affect millions worldwide. Our strategy is to develop medicines that target the IL-1β pathway, which is a central driver of the inflammatory process. Our lead asset, AVTX-009, is an anti-IL-1β monoclonal antibody currently being studied in a Phase 2 trial in hidradenitis suppurativa (HS), a chronic inflammatory skin condition that affects an estimated 1–4% of the population globally.1 AVTX-009 has the potential to treat multiple other immune mediated diseases, and we are exploring its utility in a number of additional indications.

Our mission

To transform lives with novel therapeutics that realize the promise of best-in-class and best-in-disease medicines.

Our vision

Driven by compassion and science, we develop and commercialize targeted therapeutics for people living with diseases with significant unmet clinical needs.

Avalo and the enso circle

Our name and circular mark hold special meaning for us. The name Avalo is tied to the compassion we feel for those living with chronic disease—compassion that drives us to work tirelessly towards better solutions. The open circle in our logo, called an “enso circle,” is a symbol of the strength, creativity, minimalism, and growth we continually strive to embody. It also reminds us that our mission won’t be complete until we’ve addressed the remaining unmet needs of those struggling with inflammatory diseases.

Reference: 1.Nguyen TV et al. J Eur Acad Dermatol Venereol. 2021;35(1):50-61.

The right team to bring novel IL-1β therapies to market

We share a commitment to teamwork, passion for science, and dedication to the people suffering from acute and chronic inflammatory diseases. Our cross-functional team has a deep understanding of disease pathology and clinical development of novel therapeutic targets. Our collective expertise in discovery, development, and regulatory approvals is evidenced in our strong individual track records of advancing multiple therapeutic programs to successful commercialization.

Garry A. Neil, MD
Chief Executive Officer
Mittie Doyle, MD, FACR
Chief Medical Officer
Lisa Hegg, PhD
SVP Program Management, Business Development, and Corporate Infrastructure
Colleen Matkowski
Senior Vice President, Global Regulatory Affairs and Quality Assurance
Dino C. Miano, PhD
Senior Vice President, CMC and Technical Operations
Jennifer Riley
Chief Strategy Officer
Chris Sullivan
Chief Financial Officer
Paul Varki
Chief Legal Officer

Board of directors

Michael Heffernan
Chairman of the Board
Garry A. Neil, MD
Chief Executive Officer
June Almenoff, MD, PhD
Mitchell Chan
Jonathan Goldman, MD
Rita Jain, MD
Aaron Kantoff
Gilla Kaplan, PhD
Samantha Truex